Covishield Vaccine: Nervous system disorder due to Covishield vaccine, 7 patients found in Kerala

New Delhi: Two separate studies have revealed that 11 people developed a rare neurological disorder called ‘Gillian-Barr syndrome’ after receiving the Covishield vaccine developed by AstraZeneca and Oxford University. Seven of the patients are from Kerala and four are from Nottingham, UK. All were vaccinated 10 to 22 days before the onset of the disease. In Gillian-Barr syndrome, your immune system mistakenly attacks your own brain and spinal cord. The research report was published in the Journal of Annals of Neurology on June 10.

coronavirus: Threat to Corona’s Delta Plus variant, Center warns three states including Maharashtra
delta plus variant: How effective is the vaccine against the deadly delta variant of the corona? The Center replied

Delta Plus has 22 patients in the country

There are 22 cases of Delta Plus coronavirus in the country. Of these, 16 patients are from Maharashtra and the rest are from Kerala and Madhya Pradesh, the Union Health Ministry said on Tuesday.

‘The Delta Plus virus has been found in ten countries around the world so far. That includes India, ‘said Union Health Secretary Rajesh Bhushan at a press conference. The virus has also been found in the United States, Britain, Portugal, Switzerland, Japan, Poland, Nepal, China and Russia. “The virus is a cause for concern right now,” Bhushan said. Patients with the virus have been found in Ratnagiri and Jalgaon districts of Maharashtra. Bhushan also suggested that Maharashtra, Kerala and Madhya Pradesh should take immediate steps to curb the spread of the virus.

An earlier version of the virus, Delta virus, was found in 80 countries around the world.

Delta Plus more deadly

– Slightly less contagious

– On the contrary, the virus sticks to the cells in the lungs

– Reduces the response of monoclonal antibodies

– So more lethality
coronavirus india: The third wave of coronavirus can be stopped, the solution stated by the member of the policy commissioncovid vaccine: Good news! The covacin vaccine is 77.8 percent effective in the third phase of testing